Systematic review and sequential analysis of Xuebijing Injection in treatment of systemic inflammatory response syndrome.
10.19540/j.cnki.cjcmm.20201102.501
- Author:
Zhe ZHAO
1
;
Shi-Xiang HU
2
;
Jun-Fang GUAN
1
;
Ji-Jie YI
1
;
Zhi-Wei ZHANG
1
;
Fang-Yuan CHEN
1
;
Fang-Biao XU
1
Author Information
1. Henan University of Chinese Medicine Zhengzhou 450008, China.
2. Henan Provincial Hospital of Traditional Chinese Medicine Zhengzhou 450002, China.
- Publication Type:Meta-Analysis
- Keywords:
GRADE evaluation;
Xuebijing Injection;
systematic review;
systemic inflammatory response syndrome;
trial sequential analysis
- MeSH:
Drugs, Chinese Herbal;
Humans;
Injections;
Randomized Controlled Trials as Topic;
Reproducibility of Results;
Systemic Inflammatory Response Syndrome/drug therapy*
- From:
China Journal of Chinese Materia Medica
2021;46(15):3980-3989
- CountryChina
- Language:Chinese
-
Abstract:
To systematically review the efficacy of Xuebijing Injection combined with western medicine in the treatment of systemic inflammatory response syndrome(SIRS). In this study, CBM, CNKI, Wanfang, VIP, PubMed and EMbase databases were retrieved for clinical randomized controlled trials on the effect of Xuebijing Injection combined with western medicine in the treatment of SIRS from the establishment of the database to July 31, 2020. After screening, Meta-analysis was conducted by RevMan 5.3 software, trial sequential analysis was conducted by TSA 0.9.5.10 beta software, and the evidence quality level was evaluated by GRADEprofiler 3.6.1 software. Meta-analysis showed that Xuebijing Injection combined with western medicine could reduce white blood cell count(MD=-2.32, 95%CI[-2.44,-2.21], P<0.000 01), C-reactive protein count(MD=-22.70, 95%CI[-29.61,-15.79], P<0.000 01), APACHE Ⅱ score(MD=-2.15, 95%CI[-2.43,-1.87], P<0.000 01), tumor necrosis factor alpha count(SMD=-1.23, 95%CI[-1.48,-0.99], P<0.000 01) and interleukin-6 count(SMD=-0.92, 95%CI[-1.15,-0.69], P<0.000 01), improve treatment efficiency(RR=1.39, 95%CI[1.23, 1.56], P<0.000 01), reduce incidence of multiple organ dysfunction(RR=0.47, 95%CI[0.35, 0.64], P<0.000 01) and mortality(RR=0.22, 95%CI[0.13, 0.37], P<0.000 01), which were better than western medicine treatment alone. Trial sequential analysis showed that in terms of reducing the incidence of multiple organ dysfunction and C-reactive protein count, the cumulative Z value passed through the traditional threshold, TSA threshold and expected information value, and reached the required number of cases. GRADE evaluation showed that the level of evidence was low or very low. According to the findings, Xuebijing Injection combined with western medicine is effective in treating SIRS. However, as the low quality of the included studies may affect the reliability of the conclusion, more high-quality studies shall be included for further verification in the future, so as to provide better suggestions for clinical medication.
